Back to top
more

Myovant Sciences Ltd. (MYOV)

(Delayed Data from NYSE)

$6.00 USD

6.00
240,999

-0.06 (-0.99%)

Updated Sep 20, 2019 03:57 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for MYOV

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Myovant Sciences Ltd. falls in the month of March.

All items in Millions except Per Share data.

3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Assets          
Cash & Equivalents 156 109 181 0 NA
Receivables 1 1 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 10 5 3 0 NA
Total Current Assets 167 115 184 0 NA
Net Property & Equipment 2 1 1 0 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 4 3 0 0 NA
Total Assets 173 119 185 0 NA
Liabilities & Shareholders Equity 3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Notes Payable 0 0 0 0 NA
Accounts Payable 11 5 3 0 NA
Current Portion Long-Term Debt 6 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 54 30 12 0 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 1 2 3 0 NA
Total Current Liabilities 72 37 18 0 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 1 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 93 44 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 2 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 169 81 19 0 NA
Shareholders Equity 3/31/2019 3/31/2018 3/31/2017 3/31/2016 3/31/2015
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 506 266 252 1 NA
Retained Earnings -502 -228 -85 -2 NA
Other Equity 1 0 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 4 38 167 -0 NA
Total Liabilities & Shareholder's Equity 173 119 185 0 NA
Total Common Equity 4 38 167 -0 0
Shares Outstanding 70.80 60.90 60.20 NA NA
Book Value Per Share 0.06 0.62 2.77 0.00 0.00

Fiscal Year End for Myovant Sciences Ltd. falls in the month of March.

All items in Millions except Per Share data.

6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Assets          
Cash & Equivalents 227 156 183 154 144
Receivables 0 1 1 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 9 10 12 8 6
Total Current Assets 236 167 196 164 150
Net Property & Equipment 2 2 2 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 13 4 4 3 3
Total Assets 251 173 202 168 154
Liabilities & Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Notes Payable 0 0 0 0 0
Accounts Payable 10 11 5 8 5
Current Portion Long-Term Debt 12 6 2 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 46 54 48 39 38
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 1 1 1 6
Total Current Liabilities 69 72 56 48 49
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 1 1 1 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 99 93 97 45 44
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4 1 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 171 169 155 94 94
Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 650 506 474 430 350
Retained Earnings -570 -502 -427 -356 -291
Other Equity -0 1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 80 4 47 74 60
Total Liabilities & Shareholder's Equity 251 173 202 168 154
Total Common Equity 80 4 47 74 60
Shares Outstanding 89.60 70.80 68.40 68.20 64.80
Book Value Per Share 0.89 0.06 0.68 1.09 0.93